Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18764Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Lialios, G. | en |
| dc.contributor.author | Kallitsaris, A. | en |
| dc.contributor.author | Bourantas, K. L. | en |
| dc.contributor.author | Messinis, I. E. | en |
| dc.date.accessioned | 2015-11-24T18:54:52Z | - |
| dc.date.available | 2015-11-24T18:54:52Z | - |
| dc.identifier.issn | 0024-7758 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18764 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Anemia, Iron-Deficiency/*drug therapy | en |
| dc.subject | Blood Transfusion | en |
| dc.subject | Erythropoietin/*therapeutic use | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | *Jehovah's Witnesses | en |
| dc.subject | Pregnancy | en |
| dc.subject | Pregnancy Outcome | en |
| dc.subject | Recombinant Proteins | en |
| dc.subject | *Triplets | en |
| dc.title | Recombinant human erythropoietin in a triplet pregnancy: a case report | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16419637 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2005 | - |
| heal.abstract | BACKGROUND: Women carrying triplets are at greater risk for both anemia, due to the increased demands of the developingfetuses, and peripartum hemorrhage. Jehovah's witnesses are a unique obstetric population since women of this faith refuse blood transfusion. CASE: A Jehovah's Witness with a triplet pregnancy was successfully administered recombinant human erythropoietin (rHuEpo), 200 IU/kg 3 times per week subcutaneously, in order to correct her peripartum anemia. No side effects were observed during rHuEpo therapy, and the patient delivered healthy triplets. CONCLUSION: rHuEpo can be safely administered, with a beneficial effect in pregnancy, and seems to be an effective option in preventing transfusions as demonstrated in this case in a Jehovah's Witness. | en |
| heal.journalName | J Reprod Med | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
